ArticleFrontiers in public health2025

The long-term avoided recurrences and recurrence-related cost of alectinib for postoperative adjuvant therapy in Chinese patients with early-stage ALK-positive non-small cell lung cancer.

Xuanxuan Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.